Publisher's latest report Substance Abuse Deterrents andTreatments - An Assessment of the Technological, Competitive and R&DLandscape, provides analysis of the substance abuse treatment pipeline,
stratified by stage of development and molecule type. It includes information
on the current clinical and commercial landscape, and the composition of the
substance abuse therapeutics market in terms of dominant molecule types and
targets, as well as highlighting current unmet needs.
The substance abuse treatment pipeline is dominated by
therapies for nicotine and alcohol addiction, with the 34 and 32 products in
respective active development combining to produce over 50% of the total
pipeline. Despite this, there are several promising candidates in development
targeting a range of other indications including opioid and cocaine addiction.
Various new approaches currently under investigation will see novel and
first-in-class treatments, including vaccines, redefine the current arena.
A growing treatment pipeline and continued research and investment in this field reflects the fact that current therapies for those suffering from various drug addictions remain insufficient. More than 27 million people worldwide are currently classified as problem drug users under the Nations Office on Drugs and Crime’s guidelines. Of these, only one in six has access to therapy while many countries still have no adequate services for treating substance abuse. One of the main reasons why substance abuse remains high and is so difficult to treat is that there is not yet a complete understanding of the various aspects encompassing this global issue.
Key questions answered: